OCI-LY-1

Molecular Cytogenetic Characterization of NHL Cell Lines

Spectral karyotyping (SKY) and comparative genomic hybridization (CGH) have greatly enhanced the resolution of cytogenetic analysis, enabling the identification of novel regions of rearrangement and amplification in tumor cells. 10 malignant non-Hodgkin lymphoma (NHL) cell lines, including OCI-Ly1, OCI-Ly2, OCI-Ly3, OCI-LY4, OCI-Ly7, OCI-Ly8, OCI-Ly12, OCI-Ly13.2, OCI-Ly17, and OCI-Ly18, were analyzed by G-banding, SKY, and CGH. Fig. 1 illustrates the display and classified SKY images of a representative metaphase cell from OCI-Ly17 after hybridization with SKY painting probes.

In contrast to the 52 breakpoints identified by G-banding, SKY identified 87 breakpoints, which clustered at 1q21, 7p15, 8p11, 13q21, 13q32, 14q32, 17q11, and 18q21. G-banding identified 10 translocations, including the previously described recurring translocations, t(8;14)(q24;q32) and t(14;18)(q32;q21). In contrast, SKY identified 60 translocations, including five that were recurring, t(8;14)(q24;q32), t(14;18)(q32;q21), t(4;7)(p12;q22), t(11;18)(q22;q21), and t(3;18)(q21;p11) (Fig. 2). CGH identified seven sites of high-level DNA amplification, 1q31-32, 2p12-16, 8q24, 11q23-25, 13q21-22, 13q32-34, and 18q21-23; of these, 1q31-32, 11q23-25, 13q21-22, and 13q32-34 have previously not been described as amplified in NHL.

Fig. 1 A metaphase cell from the cell line OCI-Ly17 showing display (A) and classification (B) colors. (Mehra S, et al., 2002)

Fig. 2 Representative examples of rearrangements misidentified by G-banding that SKY identified. (Mehra S, et al., 2002)

Effects of Different Concentrations of Doxorubicin on OCI-LY1 Cells

Adriamycin (doxorubicin) is an important traditional drug that exhibits cytotoxicity in DLBCL. At the concentration of 8 μmol/l of doxorubicin, the inhibition rate of OCI-LY1 cell proliferation was found to be 69.313 ± 5.359%, which was significantly higher than the inhibition rates 59.427 ± 4.145%, 39.563 ± 7.350%, 25.340 ± 4.835%, and 17.108 ± 3.957% at 4, 2, 1, and 0.5 μmol/l concentrations, respectively (P < 0.05). An increase in the concentration of doxorubicin resulted in a gradual increase in the suppression of the proliferation of OCI-LY1 cells, with significant differences between the groups (P < 0.05). The IC50 of doxorubicin used to intervene with OCI-LY1 cells was found to be 3.028 μmol/l for 24 h, which laid a foundation for future experiments. Overall, doxorubicin hindered the proliferation of DLBCL cells, with an increase in the concentration of doxorubicin enhancing the inhibition rate of DLBCL cells (Fig. 3 and 4).

Fig. 3 Images of doxorubicin interfering with the proliferation of OCI-LY1 cells. (Yan S, et al., 2022)

Fig. 4 Effect of doxorubicin on the proliferation of OCI-LY1 cells. (Yan S, et al., 2022)